{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Onset&page=2",
    "query": {
      "intervention": "Onset",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Onset&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T18:37:07.946Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00244543",
      "title": "Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "R89674 (generic name not yet established)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vistakon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2005-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-09-27",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 1,
      "location_summary": "North Andover, Massachusetts",
      "locations": [
        {
          "city": "North Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244543"
    },
    {
      "nct_id": "NCT03172026",
      "title": "Maraviroc to Augment Rehabilitation Outcomes After Stroke",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Maraviroc 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Rehabilitation therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "86 Years",
        "sex": "ALL",
        "summary": "30 Years to 86 Years"
      },
      "enrollment_count": 2,
      "start_date": "2019-08-01",
      "completion_date": "2020-10-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • White Plains, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03172026"
    },
    {
      "nct_id": "NCT03954210",
      "title": "SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy for Insomnia (CBT-I)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Sleep and Lifestyle Education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 200,
      "start_date": "2019-08-27",
      "completion_date": "2025-04-18",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954210"
    },
    {
      "nct_id": "NCT01713946",
      "title": "A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tuberous Sclerosis Complex-associated Refractory Seizures"
      ],
      "interventions": [
        {
          "name": "RAD001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Antiepileptic drug (1 to 3 only)",
          "type": "DRUG"
        },
        {
          "name": "open label RAD001 (only used for post-extension phase)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 366,
      "start_date": "2013-04-29",
      "completion_date": "2017-10-25",
      "has_results": true,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01713946"
    },
    {
      "nct_id": "NCT04623242",
      "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimers Disease",
        "Dementia",
        "Alzheimers Disease, Familial"
      ],
      "interventions": [
        {
          "name": "Gantenerumab",
          "type": "DRUG"
        },
        {
          "name": "Solanezumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo (Gantenerumab)",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo (Solanezumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 194,
      "start_date": "2012-12",
      "completion_date": "2020-03-06",
      "has_results": true,
      "last_update_posted_date": "2022-09-22",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04623242"
    },
    {
      "nct_id": "NCT04885062",
      "title": "Belun Ring Platform With an Improved Algorithm for OSA Assessment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sleep-Disordered Breathing",
        "Sleep Architecture"
      ],
      "interventions": [
        {
          "name": "Belun Ring",
          "type": "DEVICE"
        },
        {
          "name": "PSG",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Belun Technology Company Limited",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 136,
      "start_date": "2021-02-01",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04885062"
    },
    {
      "nct_id": "NCT00044239",
      "title": "Characterization of Childhood-Onset Obsessive-Compulsive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obsessive-Compulsive Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 49,
      "start_date": "2002-08-20",
      "completion_date": "2010-05-18",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Gainesville, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Logan",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044239"
    },
    {
      "nct_id": "NCT04598893",
      "title": "Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Teplizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Provention Bio, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "9 Years to 19 Years"
      },
      "enrollment_count": 188,
      "start_date": "2020-10-26",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 25,
      "location_summary": "San Diego, California • San Francisco, California • Walnut Creek, California + 22 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04598893"
    },
    {
      "nct_id": "NCT05444582",
      "title": "Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Levonorgestrel 52 MG Intrauterine System",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 35 Years · Female only"
      },
      "enrollment_count": 1404,
      "start_date": "2022-11-07",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 8,
      "location_summary": "San Jose, California • Denver, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05444582"
    },
    {
      "nct_id": "NCT00325650",
      "title": "Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prediabetic State"
      ],
      "interventions": [
        {
          "name": "Rimonabant",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Rimonabant)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 2420,
      "start_date": "2006-05",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-18",
      "last_synced_at": "2026-09-07T18:37:07.946Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00325650"
    }
  ]
}